Mamoun Younes

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus)
    Mamoun Younes
    Am J Gastroenterol 98:1200-1; author reply 1201. 2003
  2. ncbi request reprint Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Eur J Cancer 42:542-7. 2006
  3. doi request reprint Estrogen receptor β
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Arch Pathol Lab Med 135:63-6. 2011
  4. ncbi request reprint Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Arch Pathol Lab Med 131:571-5. 2007
  5. doi request reprint Gastrointestinal pathology: selected reviews from the 47th Annual Spring Symposium of the Houston Society of Clinical Pathologists, April 2007
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 132:1576. 2008
  6. ncbi request reprint Frozen section of the gastrointestinal tract, appendix, and peritoneum
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 129:1558-64. 2005
  7. doi request reprint The significance of "indefinite for dysplasia" grading in Barrett metaplasia
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 135:430-2. 2011
  8. ncbi request reprint Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia
    Xueyun Chen
    Department of Pathology, Section of Gastroenterology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Cancer Epidemiol Biomarkers Prev 13:30-3. 2004
  9. ncbi request reprint Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate
    Rile Li
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Prostate 58:193-9. 2004
  10. ncbi request reprint Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma
    Liang Liu
    Department of Pathology, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Anticancer Res 24:2919-24. 2004

Research Grants

  1. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2001
  2. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2002
  3. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2003
  4. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2002
  5. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2004
  6. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2005

Collaborators

Detail Information

Publications36

  1. ncbi request reprint P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus)
    Mamoun Younes
    Am J Gastroenterol 98:1200-1; author reply 1201. 2003
  2. ncbi request reprint Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Eur J Cancer 42:542-7. 2006
    ..Targeting of these receptors by agonist monoclonal antibodies may be of therapeutic value in patients with EA...
  3. doi request reprint Estrogen receptor β
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Arch Pathol Lab Med 135:63-6. 2011
    ..Pathologists need to be more aware of this increasingly important protein, as it will soon find its way into routine clinical practice...
  4. ncbi request reprint Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Arch Pathol Lab Med 131:571-5. 2007
    ..However, we have seen cases diagnosed as Barrett metaplasia based solely on cells that pose morphologic similarity to ITGCs on hematoxylin-eosin staining or stain positive with Alcian blue...
  5. doi request reprint Gastrointestinal pathology: selected reviews from the 47th Annual Spring Symposium of the Houston Society of Clinical Pathologists, April 2007
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 132:1576. 2008
  6. ncbi request reprint Frozen section of the gastrointestinal tract, appendix, and peritoneum
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 129:1558-64. 2005
    ..There is no room for errors in the frozen section laboratory, because a small mistake can have serious consequences. To my knowledge, no recent books or publications in the literature have dealt with this important topic...
  7. doi request reprint The significance of "indefinite for dysplasia" grading in Barrett metaplasia
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Arch Pathol Lab Med 135:430-2. 2011
    ..However, pathologists are often faced with biopsies where the crypts show dysplasia, but the surface epithelium is either uninvolved or unevaluable. We previously grouped these cases with indefinite for dysplasia (IND)...
  8. ncbi request reprint Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia
    Xueyun Chen
    Department of Pathology, Section of Gastroenterology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Cancer Epidemiol Biomarkers Prev 13:30-3. 2004
    ..Additional studies are needed to determine whether BM biopsies that are ND or LGD/IND and positive for HMGI(Y) are more likely to progress to adenocarcinoma...
  9. ncbi request reprint Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate
    Rile Li
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Prostate 58:193-9. 2004
    ..VEGF-C binds its receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) to promote growth of tumor-associated lymphatic vessels...
  10. ncbi request reprint Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma
    Liang Liu
    Department of Pathology, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Anticancer Res 24:2919-24. 2004
    ..T1 and T2, p=0.051). We conclude that ER-B1, ER-B2, ER-B3 and ER-B5 are overexpressed in EA compared to its precursor lesion BMND, suggesting a significant biological role for steroid hormones in EA...
  11. ncbi request reprint Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 106:2610-6. 2006
    ..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
  12. ncbi request reprint Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach
    Hong Dai
    Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA
    Hum Pathol 38:299-307. 2007
    ..It is possible that oncogenes and growth factors might act synergistically in promoting proliferation and/or inhibiting apoptosis, a survival strategy crucial to the development of PNI in PanCa...
  13. ncbi request reprint Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
    Georgios V Georgakis
    Department of Lymphoma Myeloma, M D Anderson Cancer Center MDACC, Houston, TX 77030, USA
    Br J Haematol 130:501-10. 2005
    ..Our data demonstrate that HGS-ETR1 and HGS-ETR2 monoclonal antibodies can induce cell death in a variety of cultured and primary lymphoma cells, and may have therapeutic value in lymphoma...
  14. ncbi request reprint Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma
    Deborah Witte
    Department of Pathology, Baylor College of Medicine, Methodist Hospital, Houston, TX, USA
    Anticancer Res 22:2555-7. 2002
    ..Larger studies with multivariate analysis are needed to determine whether ASCT2 expression is an independent prognostic marker in CRC...
  15. ncbi request reprint Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease
    Francisco Vega
    Department of Pathology, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Am J Surg Pathol 30:539-44. 2006
    ..It is as yet unknown whether this process occurs more commonly in patients with gluten sensitivity, or in other settings, and the pathogenesis is as yet undetermined...
  16. ncbi request reprint Differential expression of estrogen receptor beta isoforms in human breast cancer tissue
    Andrew Chi
    Department of Pathology, Baylor College of Medicine, Methodist Hospital, Houston, TX, USA
    Anticancer Res 23:211-6. 2003
    ....
  17. ncbi request reprint Non-dysplastic and dysplastic Barrett's mucosa and adenocarcinoma lack a subepithelial myofibroblastic cell layer
    Yve Huttenbach
    Department of Pathology, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA
    Anticancer Res 23:2261-5. 2003
    ..We hypothesize that lack of the SMF cell layer in BM may contribute to the quick progression to esophageal adenocarcinoma, which, unlike that in the colon, occurs before an exophytic lesion becomes evident...
  18. ncbi request reprint Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation
    Nicole Carlson
    Department of Pathology and Medicine, Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030, USA
    Am J Gastroenterol 97:1340-5. 2002
    ..The aim of this study was to test the hypothesis that AST may not alter malignant progression in BM if key genes involved in DNA repair and cell cycle control, particularly p53, are defective...
  19. pmc Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium
    Sheng Zhang
    Molecular Surgeon Research Center, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, United States of America
    PLoS ONE 8:e63702. 2013
    ..This is the first study to reveal the importance of monitoring SELENBP1 expression as a potential biomarker in contributing to breast cancer prevention and treatment...
  20. ncbi request reprint Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus
    Hulya Akgun
    Department of Pathology, Baylor College of Medicine and The Methodist Hospital Houston, TX 77030, USA
    Anticancer Res 22:1459-61. 2002
    ..These findings raise the possibility that esophageal adenocarcinomas may benefit from treatment and/or chemoprevention with antiestrogens, such as tamoxifen...
  21. ncbi request reprint MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
    Bei Zheng
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX 77030, USA
    Blood 102:1019-27. 2003
    ..These findings provide a proof-of-principle that inhibition of the MEK/ERK pathway may have therapeutic value in HD...
  22. ncbi request reprint Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma
    Deborah Witte
    Department of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Anticancer Res 22:1463-6. 2002
    ..05), but not with lymph node metastasis or depth of tumor invasion. Our results suggest that VEGFs promote cancer growth not only by stimulating angiogenesis, but also by acting on receptors present on the cancer cells themselves...
  23. ncbi request reprint Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin
    Ian M Jaffee
    Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Tex 77030, USA
    Arch Pathol Lab Med 130:1522-6. 2006
    ..The intestinal transcription factor CDX2 has been found to be expressed in most intestinal adenocarcinomas but in less than one half of the gastrointestinal carcinoids according to 1 study...
  24. ncbi request reprint Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma
    Laura A Granville
    U T MD Anderson Cancer Center, Houston, TX, USA
    Appl Immunohistochem Mol Morphol 13:75-9. 2005
    ..Neither antibody performed well on sarcomatous malignant mesothelioma (Zymed=2/22; DAKO=1/22). Both antibodies are useful in the diagnosis of epithelial malignant mesothelioma, although monoclonal antibody is slightly less sensitive...
  25. ncbi request reprint What is the role of cytokeratins in Barrett/cardia differentiation?
    Mamoun Younes
    Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA
    Arch Pathol Lab Med 129:181-2. 2005
    ..However, because it may be associated with premalignant lesions elsewhere in the gastric mucosa, we propose that intestinal metaplasia of the gastric cardia may have the same clinical implication as Barrett metaplasia...
  26. ncbi request reprint Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa
    Randy Wei
    Department of Pathology, Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
    Hum Pathol 33:693-6. 2002
    ..Additional studies with larger patient samples and multivariate analysis are needed to determine whether TRT expression is an independent prognostic factor in CRC...
  27. ncbi request reprint Expression of neutral amino acid transporter ASCT2 in human prostate
    Rile Li
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
    Anticancer Res 23:3413-8. 2003
    ..ASCT2 appears to be required for the glutamine metabolism in both nonmalignant and malignant prostate. ASCT2-positive PCa seems to be related to a more aggressive biological behavior. ASCT 2 seems to be involved in tumor progression...
  28. ncbi request reprint Is immunostaining for Helicobacter pylori superior to the special stain thiazine in detecting small numbers of H. pylori in gastric biopsies?
    Nirag Jhala
    Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
    Appl Immunohistochem Mol Morphol 10:82-4. 2002
    ....
  29. ncbi request reprint Is the incidence of esophageal adenocarcinomas in patients with Barrett's esophagus really overestimated?
    Mamoun Younes
    Gastroenterology 129:2125-6; author reply 2126. 2005
  30. ncbi request reprint Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  31. ncbi request reprint c-kit proto-oncogene product is rarely detected in colorectal adenocarcinoma
    Rebecca Yorke
    J Clin Oncol 21:3885-6; discussion 3886-7. 2003
  32. ncbi request reprint Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer?
    Mamoun Younes
    Gastroenterology 125:1912; author reply 1912-3. 2003
  33. ncbi request reprint Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions
    Gregory E Weitsman
    Manitoba Institute of Cell Biology, Department of Biochemistry and Medical Genetics, University of Manitoba, 675 McDermot Avenue, R3E 0V9 Winnipeg, Manitoba, Canada
    Breast Cancer Res Treat 100:23-31. 2006
    ....
  34. ncbi request reprint Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type
    Donald Earl Henson
    Department of Pathology and the Office of Cancer Prevention and Control, The George Washington University Cancer Institute, Washington, DC 20037, USA
    Arch Pathol Lab Med 128:765-70. 2004
    ..This decline has primarily included the intestinal type (Lauren classification). However, there is an impression among pathologists that the diffuse type, especially the signet ring cell subtype, has become more prevalent...
  35. ncbi request reprint Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
    Mamoun Younes
    J Clin Oncol 23:923; author reply 923-4. 2005
  36. ncbi request reprint Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance
    Katharina Clodi
    St Anna Kinderspital, Vienna, Austria
    Cancer 94:1-5. 2002
    ..In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients...

Research Grants6

  1. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2001
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..
  2. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2002
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..
  3. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2003
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..
  4. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2002
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..
  5. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2004
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..
  6. P53 AND DNA PLOIDY IN BARRETT'S METAPLASIA
    Mamoun Younes; Fiscal Year: 2005
    ..A cost analysis will be then performed to determine whether a molecular based surveillance program would be more cost-effective than current program which is based on morphologic grading of dysplasia. ..